Efficacy and Safety Study of Rasagiline Tablets in the Treatment of Parkinson’s Disease
Abstract
Objective: To evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease, in order to provide a more scientific basis for the application of the drug in Parkinson’s disease. Methods: This study is a single-arm, prospective, observational study. The trial collected patients with primary Parkinson’s disease who met the inclusion and exclusion criteria after being assessed by the investigator to evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease patients through UPDRSIII and UPDRSII scales, and evaluated the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease patients. Results: A total of 3560 patients were included in this study. 44.1% of patients had early Parkinson’s disease, 52.4% had intermediate Parkinson’s disease, and 3.5% had advanced Parkinson’s disease. The UPDRSIII (exercise capacity) score was 26.76 at baseline, 25.47 at 1 month, 24.18 at 2 months, and 23.39 at 3 months after treatment, and scores significantly improved over time (P < 0.001). The UPDRSII (ability to perform daily living) score was an average of 23.60 at baseline, 22.49 at 1 month, 21.53 at 2 months, and 21.09 at 3 months after treatment, with statistically significant differences in scores between months (P < 0.001). A total of 18 adverse events/reactions occurred in this study, and adverse symptoms eventually disappeared or resolved, without termination due to adverse events/reactions or patient discharge. Conclusion: Rasagiline tablets have significant efficacy in improving daily exercise capacity and living ability in patients with Parkinson’s disease, and have a certain safety, which supports the effectiveness of rasagiline as a treatment for Parkinson’s disease and provides new evidence for its clinical application.
References
Liu H, 2024, Early Identification and Treatment of PD. Everyone Health, 2024(17): 23.
Zhong Z, Shen P, Gao Y, 2022, Clinical Characteristics of Non-Motor Symptoms in Patients With Primary PD. Chinese Journal of Practical Neurological Diseases, 25(4): 488–492.
PD and Movement Disorders Group, Neurology Branch of Chinese Medical Association, PD and Movement Disorders Group, Neurology Branch of Chinese Medical Doctor Association, 2020, Guidelines for treatment of Parkinson's disease in China, 4th Edition. Chinese Journal of Neurology, 53(12): 973–986.
PD and Movement Disorders Group, Neurology Branch of Chinese Medical Association, PD and Movement Disorders Specialty of Neurology Branch of Chinese Medical Doctor Association, 2016, Diagnostic Criteria for PD in China (2016 Edition). Chinese Journal of Neurology, 49(4): 268–271.
Xu J, Li J, Li Y, et al., 2021, Research on Nicotine Inhibition of Monoamine Oxidase B Activity and Its Anti-PD Effect. Chinese Journal of Tobacconima, 27(3): 88–96.
Fu S, Liang Z, 2021, Research on the Treatment of PD Gait Disorder With Monoamine Oxidase B Inhibitors. Journal of Clinical Neurology, 34(6): 462–465.
Liao P, 2014, Observation of the Efficacy of Rasagiline Mesylate Combined With Levodopa in the Treatment of Primary PD With Fluctuating Motor Symptoms. Journal of Practical Cardiovascular, Cerebropulmonary and Vascular Diseases, 22(9): 78–79.
Gong D, 2018, Research on the Synthesis Process of Rasagiline Mesylate of the Second-Generation Monoamine Oxidase Inhibitor, thesis, Jilin University.
Wu Y, Zhou D, 2019, Observation on the Efficacy of Levodopa Preparations Combined With Rasagiline Mesylate Tablets in the Treatment of Primary PD Patients With Fluctuating Motor Symptoms. China Pharmacoeconomics, 14(2): 90–92 + 128.
Solís-García J, Mínguez-Mínguez S, Groot P, et al., 2013, Rasagiline Meta-Analysis: A Spotlight on Clinical Safety and Adverse Events When Treating Parkinson’s Disease. Expert Opin Drug Saf, 12(4): 479–486.
Shi R, Gao X, Cui J, et al., 2024, Research Progress on 5-Hydroxytryptamine and PD Non-Motor Symptoms. Chinese Journal of Modern Neurological Diseases, 24(6): 497–501.
